Differential effect of desglycinamide9-(Arg8)-vasopressin on cognitive functions of diabetes insipidus and alcoholic patients.
Intranasal treatment with desglycinamide9-(Arg8)-vasopressin (DGAVP) improved certain aspects of cognitive functions of patients with acquired and congenital diabetes insipidus and of alcoholic patients with mild cognitive impairments. Patients with Korsakoff's syndrome, presenting with severe cognitive impairments, were resistent to DGVP treatment. DGAVP treatment did not affect blood pressure and water metabolism. The action of DGAVP on cognitive functions is probably mediated by centrally located target sites and may be expressed only in patients in whom these target sites are unimpaired.
Laczi
F
F
László
F A
FA
Kovács
G L
GL
Telegdy
G
G
Szász
A
A
Szilárd
J
J
van Ree
J M
JM
de Wied
D
D
D000281:Administration, Intranasal; D000328:Adult; D000368:Aged; D000425:Alcohol Amnestic Disorder / Q000188:drug therapy* / Q000523:psychology; D000437:Alcoholism / Q000188:drug therapy* / Q000523:psychology; D001127:Arginine Vasopressin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D002986:Clinical Trials as Topic; D003071:Cognition / Q000187:drug effects*; D003919:Diabetes Insipidus / Q000151:congenital / Q000188:drug therapy* / Q000523:psychology; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011581:Psychological Tests
D001127:Arginine Vasopressin; C015119:argipressin, des-GlyNH2(9)-